Cagrilintide

GLP-1 / MetabolicResearch Use Only

Also known as: AM833, long-acting amylin analog

Cagrilintide is a long-acting amylin analog commonly referenced in metabolic research literature. Studies describe its action on amylin receptor pathways related to satiety and gastric emptying. It is frequently discussed in combination with GLP-1 agonists in the research setting.

Typical range (research)

Research literature commonly references escalating weekly amounts studied up to roughly ~4.5 mg/week in trials

Half-life

~7–8 days

Route

Subcutaneous (research)

Common use

Metabolic and appetite-regulation research

Common vial sizes

5 mg · 10 mg

Storage

Store lyophilized powder refrigerated (2–8°C) and protected from light; once reconstituted, keep refrigerated and use within the timeframe supported by stability data.

Stacking notes

Frequently referenced alongside semaglutide as a combined amylin/GLP-1 research approach (sometimes described as CagriSema). Combining metabolic agents compounds gastrointestinal effects.

Reported side effects

NauseaReduced appetiteGastrointestinal upset

Regulatory note: Investigational; not approved in Canada or the US. Under clinical development, often studied in combination with semaglutide. Research-grade material is not for human use.

Calculate a dose →

Dose figures are ranges commonly referenced in research literature, not recommendations or medical advice. Not for human or veterinary use. Consult a licensed physician.